7.7.8. summary: treatment algorithm metastatic urothelial cancer update 2024. figure 7.2 summarises treatment algorithm metastatic bc based evidence discussed text above. patients treatment-naive muc divided two broad categories: eligible combination therapies ineligible combination therapies. distinction two groups currently based eligibility criteria pivotal trial ev-302/keynote 39a. criteria include ecog performance status 0-2, gfr ≥30ml/min adequate organ functions eligibility treatment ev pembrolizumab. combination ev plus checkpoint inhibitor pembrolizumab represents new standard care patients deemed fit combination therapies. patients might eligible refuse treatment ev including patients uncontrolled diabetes, peripheral neuropathy grade ≥2 pre-existing significant skin disorders, platinum-based chemotherapy integration immune checkpoint inhibitors represents preferred options. regards platinum-based chemotherapy, definitions grouped according platinum-eligibility based clear definitions. platinum-based chemotherapy, cisplatin preferred carboplatin. patients cisplatin-ineligible carboplatin-eligible receive gemcitabine- carboplatin combination chemotherapy. case positive pd-l1 status, treatment checkpoint inhibitors (atezolizumab pembrolizumab) could alternative option. patients unfit cisplatin carboplatin (platinum-unfit) considered immunotherapy (fda approved irrespective pd-l1 status, ema approved pd-l1 positive patients) receive bsc. cases disease stabilization better platinum-based chemotherapy switch, maintenance treatment io (avelumab) recommended. alternatively, patients followed closely receive second-line immunotherapy time progression (pembrolizumab). recommended determine fgfr mutation status deciding further-line treatment. patients fgfr3 mutations candidates fgfr inhibitor treatment. enfortumab vedotin therapy standard case progression platinum chemotherapy io, however based ev-302/keynote 39a, majority patients candidates ev plus pembrolizumab first-line setting. optimal sequence novel agents potential combinations subject many ongoing trials. generally recommended treat patients within ongoing clinical trials whenever possible.